Peptide therapy claims on TikTok: separating signal from hype

What did @lee_maasen actually say?

The creator told a commenter named Dave that research on epithalon suggests a dose of "5 to 10 milligrams, either capsule form or subcutaneous injection, 10 to 20 straight days." They also added a disclaimer that research peptides are "not for human consumption," which is the standard legal hedge you see across peptide content. The full protocol pitch came with an upsell to a paid peptide community where dosing, sourcing, stacking, and conversions are supposedly covered in more depth.

To be clear about what was and wasn't said: the creator did not claim epithalon treats a specific disease. They framed everything as "research says," which at least keeps them out of direct therapeutic territory. But quoting specific milligram ranges and day counts, then steering people to a paid community where they'll learn to use those ranges on themselves, is threading a needle that doesn't hold up under scrutiny.

Does the science back this up?

Loosely, yes, those numbers are in the ballpark of what small-scale and animal studies have used. But "research suggests" is doing a lot of heavy lifting here, because the research on epithalon in humans is thin, dated, and mostly from a single Russian lab.

Epithalon (also spelled epitalon) is a synthetic tetrapeptide derived from epithalamin, a polypeptide extract of the pineal gland. The bulk of published work comes from Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson et al. (2002, Neuroendocrinology Letters) reported effects on melatonin secretion and telomerase activity in aging subjects, and a subsequent review (Khavinson, 2002, Annals of the New York Academy of Sciences) catalogued broader bioregulatory effects. The doses used in that human-adjacent work ranged roughly from 3 to 10mg per course. So the 5-10mg claim has a basis in what those protocols looked like.

The problem is that independent replication in peer-reviewed Western journals is sparse. Most citations in online peptide communities trace back to the same Russian group. That is not automatically disqualifying, but it should make anyone pause before treating these numbers as settled science.

What did they get wrong (or right)?

The dose range is not fabricated. Credit where it is due: 5-10mg daily for a 10-20 day course does reflect the structure of protocols described in Khavinson's published work. They didn't pull those numbers from thin air.

What they got wrong, or at least insufficiently addressed, is the bioavailability question around oral capsule delivery. Peptides are notoriously degraded in the gastrointestinal tract. The subcutaneous injection route has at least theoretical support for peptide absorption. Oral capsule delivery of epithalon, by contrast, has essentially no peer-reviewed pharmacokinetic data supporting meaningful systemic bioavailability. Presenting both as equivalent options, as the creator does, is misleading. There is a meaningful difference between those routes that the research does not treat as interchangeable.

The disclaimer that these are "not for human consumption" is also functionally hollow when paired with specific dosing protocols and an invitation to a paid community to learn how to use them. Regulatory bodies including the FDA have flagged this framing before as a shield that doesn't change the practical intent of the content.

What should you actually know?

Epithalon is not approved by the FDA for any therapeutic use in humans. It is not available as a licensed pharmaceutical in the United States. It is sold by research chemical suppliers under the caveat that it is for laboratory research only, and that caveat exists for legal reasons, not because the research community is running bench studies on it at scale.

The telomerase activation angle, which is often the headline claim in epithalon content, comes primarily from in vitro and animal studies. Telomerase activity in a cell culture dish does not automatically translate to meaningful anti-aging effects in a living human body. That connection has not been established in rigorous human trials.

If you are interested in longevity-related interventions, the honest answer is that the human evidence base for most peptides in this category is early-stage at best. A physician who specializes in this area and has access to your full health history is the appropriate starting point, not a TikTok comment thread or a subscription community run by a content creator.